{"id":2662,"date":"2023-05-11T19:55:00","date_gmt":"2023-05-11T19:55:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/"},"modified":"2023-05-11T19:55:00","modified_gmt":"2023-05-11T19:55:00","slug":"xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/","title":{"rendered":"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>Styrelsen f\u00f6r XVIVO Perfusion AB (publ) (\u201d<strong>XVIVO<\/strong>\u201d) har, med st\u00f6d av bemyndigande l\u00e4mnat av \u00e5rsst\u00e4mman den 25 april 2023, fattat beslut om en nyemission av 67\u00a0551 aktier. R\u00e4tt att teckna aktierna tillkommer endast Avionord S.r.l., s\u00e4ljaren av aktierna i XVIVO S.r.l. som XVIVO f\u00f6rv\u00e4rvade i november 2022. Betalning ska ske genom kvittning. Sk\u00e4len till avvikelse fr\u00e5n aktie\u00e4garnas f\u00f6retr\u00e4desr\u00e4tt \u00e4r att emissionen genomf\u00f6rs som en s.k. kvittningsemission d\u00e4r teckningslikviden erl\u00e4ggs genom kvittning av fordringar mot XVIVO i form av till\u00e4ggsk\u00f6peskilling f\u00f6r f\u00f6rv\u00e4rvet av XVIVO S.r.l. S\u00e5ledes \u00e4r det inte m\u00f6jligt att genomf\u00f6ra emissionen med f\u00f6retr\u00e4desr\u00e4tt f\u00f6r befintliga aktie\u00e4gare.<\/p>\n<p>Till\u00e4ggsk\u00f6peskillingen om totalt 27\u00a0170 786,35 kronor, som har ber\u00e4knats i enlighet med aktie\u00f6verl\u00e5telseavtalet, ska erl\u00e4ggas med 40 procent i kontanter och resterande 60 procent i aktier i XVIVO. Som likvid f\u00f6r aktierna ska Avionord S.r.l. kvitta deras fordran p\u00e5 XVIVO om 16\u00a0319\u00a0001,60 kronor.<\/p>\n<p>Till\u00e4ggsk\u00f6peskillingen har i enlighet med aktie\u00f6verl\u00e5telseavtalet fastst\u00e4llts enligt en \u00f6verenskommen formel. Teckningskursen uppg\u00e5r till cirka 241,58 kronor och motsvarar aktiens marknadsv\u00e4rde ber\u00e4knad efter den genomsnittliga volymviktade aktiekursen p\u00e5 Nasdaq Stockholm under perioden fr\u00e5n och med den 31 mars 2023 till och med den 17 april 2023. Genom nyemissionen kommer XVIVOs aktiekapital att \u00f6ka med 1\u00a0726,519401\u00a0kronor.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-fb9cf3b124f9\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com<br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-da5f5ee9f867\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/8599d618-d855-4fc6-b259-df6bdd497425\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar.pdf\" rel=\"noopener\" target=\"_blank\">XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Styrelsen f\u00f6r XVIVO Perfusion AB (publ) (\u201dXVIVO\u201d) har, med st\u00f6d av bemyndigande l\u00e4mnat av \u00e5rsst\u00e4mman den 25 april 2023, fattat&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2662","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-listing","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Styrelsen f\u00f6r XVIVO Perfusion AB (publ) (\u201dXVIVO\u201d) har, med st\u00f6d av bemyndigande l\u00e4mnat av \u00e5rsst\u00e4mman den 25 april 2023, fattat...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\\\/\",\"name\":\"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2023-05-11T19:55:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO","og_description":"Styrelsen f\u00f6r XVIVO Perfusion AB (publ) (\u201dXVIVO\u201d) har, med st\u00f6d av bemyndigande l\u00e4mnat av \u00e5rsst\u00e4mman den 25 april 2023, fattat...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/","name":"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2023-05-11T19:55:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-genomfor-nyemission-av-aktier-genom-kvittning-av-fordringar\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) genomf\u00f6r nyemission av aktier genom kvittning av fordringar"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2662","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2662"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}